acic 200 mg tabletes
sandoz d.d., slovenia - aciklovīrs - tablete - 200 mg
aciclovir jonax 50 mg/g krēms
stada arzneimittel ag, germany - aciklovīrs - krēms - 50 mg/g
acic 5% krēms
sandoz d.d., slovenia - aciklovīrs - krēms - 50 mg/g
valaciclovir actavis 1000 mg apvalkotās tabletes
teva b.v., netherlands - valaciklovīrs - apvalkotā tablete - 1000 mg
valaciclovir actavis 500 mg apvalkotās tabletes
teva b.v., netherlands - valaciklovīrs - apvalkotā tablete - 500 mg
aciclovir actavis 50 mg/g krēms
teva b.v., netherlands - aciklovīrs - krēms - 50 mg/g
aciclovir medochemie 250 mg pulveris infūziju šķīduma pagatavošanai
medochemie ltd., cyprus - aciklovīrs - pulveris infūziju šķīduma pagatavošanai - 250 mg
aciclovir unifarma 50 mg/g krēms
unifarma, sia, latvia - aciklovīrs - krēms - 50 mg/g
verzenios
eli lilly nederland b.v. - abemaciclib - krūts audzējs - antineoplastiski līdzekļi - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
acic 200 mg tabletes
hexal ag, germany - aciklovīrs - tablete - 200 mg